GET DAILY SIGNALSBio-Rad Laboratories (BIO) Shares Drop -10.12% After Q1 Earnings Miss and Lowered Guidance
Key Takeaways
- BIO shares plunged 10.12% to $251.77 from the previous close of $280.12.
- The selloff followed first-quarter 2026 earnings that included a $527.1 million net loss driven by a $738.2 million investment impairment.
- Management trimmed full-year guidance, projecting currency-neutral revenue growth of -3% to +0.5%, citing weak demand and currency headwinds.
- Trading volume surged above average levels, reflecting heavy investor reaction.
- The move diverged from a modestly lower biotech sector and rising broader market indices.
- Traders will monitor execution on cost controls, regional demand recovery, and second-quarter results.
BIO's Post-Earnings Plunge
Bio-Rad Laboratories (BIO), a leading developer and manufacturer of life science research and clinical diagnostic products, experienced a sharp 10.12% decline in its shares to $251.77 from the prior close of $280.12. From what I see, this drop was triggered by the company's first-quarter 2026 results, which revealed a substantial net loss and a revision to its annual guidance, leading to a quick market response during today's session.
Breaking Down the Q1 Results and Guidance
In the first quarter, Bio-Rad posted revenue of $592.1 million, up 1.1% year-over-year and slightly beating expectations on a currency-neutral basis. That said, the headline net loss of $527.1 million dominated the narrative, largely due to a $738.2 million non-cash investment impairment. Adjusted earnings per share of $1.89 fell short of analyst estimates.
Management pointed to ongoing headwinds like unfavorable foreign exchange effects, weakening academic demand, and Middle East disruptions. In light of these pressures, they narrowed full-year currency-neutral revenue growth guidance to -3% to +0.5%, a step back from earlier projections. One thing that stands out to me is how these macroeconomic factors are weighing on the outlook.
To better understand BIO's position relative to peers, I checked it against industry benchmarks using Tickeron’s AI Screener.
Trading Volume and Sector Comparison
Trading volume jumped well above the typical 300,000 shares, underscoring the strong selling as investors processed the earnings shortfall. BIO's decline far exceeded the biotech sector's, with the SPDR S&P Biotech ETF (XBI) down 1.7% and the iShares Biotechnology ETF (IBB) off 1.2%, even as the S&P 500 ETF (SPY) rose nearly 0.5%.
On the technical side, the stock broke below recent support near $273, gaining downside speed after the earnings release. I’m watching these levels closely for signs of stabilization.
Trending AI Robots
In my own research and trading routine, I frequently turn to Tickeron’s Trending AI Robots page to spot top-performing AI-driven bots suited to the current environment. It curates the strongest performers from hundreds of bots across thousands of tickers, based on metrics like recent win rates, Sharpe ratios, and strategy timeframes—from momentum and mean reversion to sector plays. This has helped me navigate volatility effectively, and it’s worth exploring to potentially sharpen your approach in uncertain markets like this one.
Looking Ahead for BIO
Investors, including myself, will be paying close attention to Bio-Rad's progress in steadying demand across its Life Science and Clinical Diagnostics segments, despite currency and geopolitical challenges. The second-quarter earnings, due in late July 2026, should shed light on cost controls and regional improvements. Analyst views are mixed following recent downgrades, and broader biotech dynamics—such as funding flows and regulations—could play a role, along with economic risks.
To gauge potential patterns here, I’ve also looked at Tickeron’s AI Pattern Search Engine.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full Disclaimers and Limitations.
Contributor
Financial writer and active order flow futures trader with a focus on fundamental analysis, macroeconomic factors, and equity research. I make in-depth blogs on stocks and ETFs, bridging the gap between raw market data and real-world trading decisions.
Momentum Indicator for BIO turns positive, indicating new upward trend
BIO saw its Momentum Indicator move above the 0 level on October 22, 2026. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 96 similar instances where the indicator turned positive. In 74 of the 96 cases, the stock moved higher in the following days. The odds of a move higher are at 77%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where BIO's RSI Oscillator exited the oversold zone, 19 of 28 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 68%.
The Moving Average Convergence Divergence (MACD) for BIO just turned positive on October 23, 2026. Looking at past instances where BIO's MACD turned positive, the stock continued to rise in 37 of 51 cases over the following month. The odds of a continued upward trend are 73%.
Following a +3.41% 3-day Advance, the price is estimated to grow further. Considering data from situations where BIO advanced for three days, in 194 of 299 cases, the price rose further within the following month. The odds of a continued upward trend are 65%.
Bearish Trend Analysis
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 45 of 64 cases where BIO's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 70%.
BIO moved below its 50-day moving average on October 30, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for BIO crossed bearishly below the 50-day moving average on October 12, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 10 of 14 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 71%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where BIO declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 69%.
BIO broke above its upper Bollinger Band on October 27, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for BIO entered a downward trend on October 12, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 2 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 41 (best 1 - 100 worst), indicating steady price growth. BIO’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron SMR rating for this company is 87 (best 1 - 100 worst), indicating slightly better than average sales and a considerably profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Valuation Rating of 91 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.365) is normal, around the industry mean (4.204). P/E Ratio (44.491) is within average values for comparable stocks, (1.723). Projected Growth (PEG Ratio) (4.006) is also within normal values, averaging (11.253). Dividend Yield (0.000) settles around the average of (0.010) among similar stocks. P/S Ratio (3.940) is also within normal values, averaging (40.124).
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. BIO’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a manufacturer of life science research products and clinical diagnostics
Industry MedicalNursingServices
Advertisement